Wells Fargo set a $18.00 target price on Mallinckrodt (NYSE:MNK) in a research report sent to investors on Friday. The firm currently has a hold rating on the stock.
MNK has been the subject of several other research reports. Oppenheimer restated a hold rating on shares of Mallinckrodt in a research report on Tuesday, February 27th. Zacks Investment Research upgraded shares of Mallinckrodt from a strong sell rating to a hold rating in a research report on Tuesday, January 9th. Goldman Sachs restated a hold rating on shares of Mallinckrodt in a research report on Monday, January 1st. Canaccord Genuity set a $24.00 price target on shares of Mallinckrodt and gave the stock a hold rating in a research report on Tuesday, December 26th. Finally, Cantor Fitzgerald set a $42.00 price target on shares of Mallinckrodt and gave the stock a buy rating in a research report on Tuesday, February 27th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the company. Mallinckrodt currently has a consensus rating of Hold and an average price target of $38.50.
Mallinckrodt (NYSE:MNK) traded up $0.32 during mid-day trading on Friday, reaching $16.09. 5,090,309 shares of the company’s stock traded hands, compared to its average volume of 5,621,703. The company has a current ratio of 2.18, a quick ratio of 1.85 and a debt-to-equity ratio of 0.98. Mallinckrodt has a 12-month low of $15.27 and a 12-month high of $49.12. The company has a market capitalization of $1,361.74, a price-to-earnings ratio of 0.71, a price-to-earnings-growth ratio of 0.33 and a beta of 1.06.
Mallinckrodt (NYSE:MNK) last released its earnings results on Tuesday, February 27th. The company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.29. The firm had revenue of $792.30 million during the quarter, compared to analyst estimates of $769.91 million. Mallinckrodt had a net margin of 66.25% and a return on equity of 13.43%. The firm’s revenue for the quarter was down 4.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.91 earnings per share. equities research analysts predict that Mallinckrodt will post 6.22 earnings per share for the current fiscal year.
Hedge funds have recently bought and sold shares of the stock. LMR Partners LLP acquired a new stake in Mallinckrodt in the fourth quarter worth about $2,630,000. Fox Run Management L.L.C. acquired a new stake in Mallinckrodt in the fourth quarter worth about $1,064,000. Schwab Charles Investment Management Inc. lifted its holdings in Mallinckrodt by 6.9% in the third quarter. Schwab Charles Investment Management Inc. now owns 433,563 shares of the company’s stock worth $16,203,000 after purchasing an additional 27,908 shares during the period. Virtu Financial LLC lifted its holdings in Mallinckrodt by 78.2% in the fourth quarter. Virtu Financial LLC now owns 16,308 shares of the company’s stock worth $368,000 after purchasing an additional 7,159 shares during the period. Finally, K2 Principal Fund L.P. lifted its holdings in Mallinckrodt by 143.7% in the fourth quarter. K2 Principal Fund L.P. now owns 113,600 shares of the company’s stock worth $2,563,000 after purchasing an additional 373,600 shares during the period. 97.38% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.dispatchtribunal.com/2018/03/17/mallinckrodt-mnk-given-a-18-00-price-target-at-wells-fargo.html.
Mallinckrodt Company Profile
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.